Preventing Vasospasm Improves Outcome After Aneurysmal Subarachnoid Hemorrhage: Rationale and Design of CONSCIOUS-2 and CONSCIOUS-3 Trials

被引:53
作者
Macdonald, R. Loch [1 ]
Higashida, Randall T. [2 ]
Keller, Emanuela [3 ]
Mayer, Stephan A. [4 ]
Molyneux, Andy [10 ]
Raabe, Andreas [5 ]
Vajkoczy, Peter [6 ]
Wanke, Isabel [7 ]
Frey, Aline [8 ]
Marr, Angelina [8 ]
Roux, Sebastien [8 ]
Kassell, Neal F. [9 ]
机构
[1] Univ Toronto, St Michaels Hosp, Div Neurosurg, Toronto, ON M5B 1W8, Canada
[2] Univ Calif San Francisco, Med Ctr, Div Neurointervent Radiol, San Francisco, CA 94143 USA
[3] Univ Spital Zurich, Neurochirurg Klin, Zurich, Switzerland
[4] Columbia Univ, Dept Neurol, New York, NY USA
[5] Univ Klin Neurochirurg, Inselspital Bern, Bern, Switzerland
[6] Charite Univ Med Berlin, Dept Neurosurg, Berlin, Germany
[7] Clin Hirslanden, Zurich, Switzerland
[8] Actel Pharmaceut Ltd, Allschwil, Switzerland
[9] Univ Virginia, Dept Neurosurg, Charlottesville, VA USA
[10] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Surg, Oxford OX3 9DU, England
关键词
Aneurysmal subarachnoid hemorrhage; Cerebral vasospasm; Clazosentan; CONSCIOUS studies; Clinical outcome; CEREBRAL VASOSPASM; RECEPTOR ANTAGONIST; DOUBLE-BLIND; CLAZOSENTAN; INFARCTION; THERAPY; STROKE; IMPAIRMENT; ENDOTHELIN; GUIDELINES;
D O I
10.1007/s12028-010-9433-3
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Cerebral vasospasm after aneurysmal subarachnoid hemorrhage (aSAH) is a frequent but unpredictable complication associated with poor outcome. Current vasospasm therapies are suboptimal; new therapies are needed. Clazosentan, an endothelin receptor antagonist, has shown promise in phase 2 studies, and two randomized, double-blind, placebo-controlled phase 3 trials (CONSCIOUS-2 and CONSCIOUS-3) are underway to further investigate its impact on vasospasm-related outcome after aSAH. Here, we describe the design of these studies, which was challenging with respect to defining endpoints and standardizing endpoint interpretation and patient care. Main inclusion criteria are: age 18-75 years; SAH due to ruptured saccular aneurysm secured by surgical clipping (CONSCIOUS-2) or endovascular coiling (CONSCIOUS-3); substantial subarachnoid clot; and World Federation of Neurosurgical Societies grades I-IV prior to aneurysm-securing procedure. In CONSCIOUS-2, patients are randomized 2:1 to clazosentan (5 mg/h) or placebo. In CONSCIOUS-3, patients are randomized 1:1:1 to clazosentan 5, 15 mg/h, or placebo. Treatment is initiated within 56 h of aSAH and continued until 14 days after aSAH. Primary endpoint is a composite of mortality and vasospasm-related morbidity within 6 weeks of aSAH (all-cause mortality, vasospasm-related new cerebral infarction, vasospasm-related delayed ischemic neurological deficit, neurological signs or symptoms in the presence of angiographic vasospasm leading to rescue therapy initiation). Main secondary endpoint is extended Glasgow Outcome Scale at week 12. A critical events committee assesses all data centrally to ensure consistency in interpretation, and patient management guidelines are used to standardize care. Results are expected at the end of 2010 and 2011 for CONSCIOUS-2 and CONSCIOUS-3, respectively.
引用
收藏
页码:416 / 424
页数:9
相关论文
共 34 条
[2]   Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage A Statement for Healthcare Professionals From a Special Writing Group of the Stroke Council, American Heart Association [J].
Bederson, Joshua B. ;
Connolly, E. Sander, Jr. ;
Batjer, H. Hunt ;
Dacey, Ralph G. ;
Dion, Jacques E. ;
Diringer, Michael N. ;
Duldner, John E., Jr. ;
Harbaugh, Robert E. ;
Patel, Aman B. ;
Rosenwasser, Robert H. .
STROKE, 2009, 40 (03) :994-1025
[3]  
Brandt, 1988, NEUROPSY NEUROPSY BE, V1, P111, DOI DOI 10.1001/ARCHNEUR.1993.00540060039014
[4]   New insights into the causes and therapy of cerebral vasospasm following subarachnoid hemorrhage [J].
Crowley, R. Webster ;
Medel, Ricky ;
Kassell, Neal F. ;
Dumont, Aaron S. .
DRUG DISCOVERY TODAY, 2008, 13 (5-6) :254-260
[5]   Relationship between vasospasm, cerebral perfusion, and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage [J].
Dankbaar, Jan W. ;
Rijsdijk, Mienke ;
van der Schaaf, Irene C. ;
Velthuis, Birgitta K. ;
Wermer, Marieke J. H. ;
Rinkel, Gabriel J. E. .
NEURORADIOLOGY, 2009, 51 (12) :813-819
[6]   Calcium antagonists for aneurysmal subarachnoid haemorrhage [J].
Dorhout Mees, S. M. ;
Rinkel, G. J. E. ;
Feigin, V. L. ;
Algra, A. ;
van den Bergh, W. M. ;
Vermeulen, M. ;
van Gijn, J. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (03)
[7]  
DUMONT AS, 2010, STROKE IN PRESS
[8]   Prophylactic hyperdynamic postoperative fluid therapy after aneurysmal subarachnoid hemorrhage: A clinical, prospective, randomized, controlled study [J].
Egge, A ;
Waterloo, K ;
Sjoholm, H ;
Solberg, T ;
Ingebrigtsen, T ;
Romner, B .
NEUROSURGERY, 2001, 49 (03) :593-605
[9]   THE UNITED-KINGDOM TRANSIENT ISCHEMIC ATTACK (UK-TIA) ASPIRIN TRIAL - FINAL RESULTS [J].
FARRELL, B ;
GODWIN, J ;
RICHARDS, S ;
WARLOW, C .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1991, 54 (12) :1044-1054
[10]   Predictors of cerebral infarction in patients with aneurysmal subarachnoid hemorrhage [J].
Fergusen, Sherise ;
Macdonald, R. Loch .
NEUROSURGERY, 2007, 60 (04) :658-667